Skip to main content
. Author manuscript; available in PMC: 2023 Nov 27.
Published in final edited form as: J Am Board Fam Med. 2023 Sep 13;36(5):777–788. doi: 10.3122/jabfm.2022.220391R2

Table 2.

Encounters with a recommendation to start a hypertension, diabetes, statin, or tobacco cessation medication stratified by those where a prescription was versus was not written within 1 week of encounter

All Encounters with a Recommendation (N = 106,769) Recommendations with a Prescription within 1 Week (N = 35,078) Recommendations with No Prescription within 1 Week (N = 71,691) p-value

GROUP <0.001
Intervention - CDS Used 15.2 16.2 14.7
Intervention - CDS Not Used 42.2 41.2 42.6
Control 42.7 42.6 42.7
ENCOUNTER RISK
Avg. Reversible Risk (SD) 10.4 (10.3) 11.5 (11.4) 9.8 (9.7) <0.001
Avg. 10-Year ASCVD Risk (SD) 17.2 (12.8) 17.9 (13.4) 16.8 (12.4) <0.001
Avg. Age at Encounter, years (SD) 58.5 (8.8) 57.9 (8.7) 58.8 (8.8) <0.001
Avg. No. Visits During Study (SD) 7.1 (6.2) 7.1 (5.8) 7.1 (6.3) <0.001
SEX <0.001
Female 52.2 51.3 53.6
ETHNICITY <0.001
Hispanic 25.5 30.4 23.2
Non-Hispanic 70.9 66.2 73.2
Unknown Ethnicity 3.6 3.4 3.7
RACE <0.001
Asian 4.0 4.4 3.8
Black 19.7 23.6 17.8
other * 2.9 2.6 3.1
white 65.7 61.2 67.9
unknown 7.7 8.2 7.4
INSURANCE AT ENCOUNTER <0.001
Medicaid 34.1 33.5 34.5
Medicare 34.9 29.3 37.7
Other Public 3.0 3.5 2.7
Private 13.2 13.4 13.1
Uninsured 14.8 20.3 12.1
FPL AT ENCOUNTER <0.001
<138% 53.0 55.1 51.9
≥138% 16.9 16.8 17.0
Missing 30.1 28.2 31.0
AVG APPT LENGTH (mins) <0.001
5–15 mins 17.7 17.4 17.9
≥20 mins 82.0 82.2 81.9
missing 0.3 0.4 0.2
AVG TIME BEHIND SCHEDULE (mins) 0.024
≤10 mins 76.0 75.6 76.2
>10 mins 24.0 24.4 23.8
*

Other race includes American Indian, Alaska Native, Native Hawaiian, Pacific Islander, those who selected more than one race, and all other race